|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRFBP1 |
Gene summary for SRFBP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRFBP1 | Gene ID | 153443 |
| Gene name | serum response factor binding protein 1 | |
| Gene Alias | BUD22 | |
| Cytomap | 5q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8NEF9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 153443 | SRFBP1 | LZE4T | Human | Esophagus | ESCC | 5.85e-07 | 1.80e-01 | 0.0811 |
| 153443 | SRFBP1 | LZE8T | Human | Esophagus | ESCC | 6.69e-03 | 1.48e-01 | 0.067 |
| 153443 | SRFBP1 | LZE24T | Human | Esophagus | ESCC | 6.54e-11 | 2.13e-01 | 0.0596 |
| 153443 | SRFBP1 | P2T-E | Human | Esophagus | ESCC | 1.09e-32 | 5.43e-01 | 0.1177 |
| 153443 | SRFBP1 | P4T-E | Human | Esophagus | ESCC | 9.67e-14 | 3.05e-01 | 0.1323 |
| 153443 | SRFBP1 | P5T-E | Human | Esophagus | ESCC | 1.74e-12 | 2.12e-01 | 0.1327 |
| 153443 | SRFBP1 | P8T-E | Human | Esophagus | ESCC | 4.28e-08 | 2.06e-01 | 0.0889 |
| 153443 | SRFBP1 | P9T-E | Human | Esophagus | ESCC | 3.78e-09 | 2.01e-01 | 0.1131 |
| 153443 | SRFBP1 | P10T-E | Human | Esophagus | ESCC | 2.36e-17 | 2.77e-01 | 0.116 |
| 153443 | SRFBP1 | P11T-E | Human | Esophagus | ESCC | 1.52e-07 | 2.42e-01 | 0.1426 |
| 153443 | SRFBP1 | P12T-E | Human | Esophagus | ESCC | 5.56e-18 | 4.03e-01 | 0.1122 |
| 153443 | SRFBP1 | P15T-E | Human | Esophagus | ESCC | 4.50e-13 | 3.19e-01 | 0.1149 |
| 153443 | SRFBP1 | P16T-E | Human | Esophagus | ESCC | 1.39e-14 | 3.80e-01 | 0.1153 |
| 153443 | SRFBP1 | P17T-E | Human | Esophagus | ESCC | 1.00e-08 | 4.17e-01 | 0.1278 |
| 153443 | SRFBP1 | P19T-E | Human | Esophagus | ESCC | 1.28e-03 | 5.19e-01 | 0.1662 |
| 153443 | SRFBP1 | P20T-E | Human | Esophagus | ESCC | 9.14e-20 | 5.33e-01 | 0.1124 |
| 153443 | SRFBP1 | P21T-E | Human | Esophagus | ESCC | 3.40e-19 | 2.97e-01 | 0.1617 |
| 153443 | SRFBP1 | P22T-E | Human | Esophagus | ESCC | 1.47e-21 | 3.92e-01 | 0.1236 |
| 153443 | SRFBP1 | P23T-E | Human | Esophagus | ESCC | 1.32e-22 | 5.68e-01 | 0.108 |
| 153443 | SRFBP1 | P24T-E | Human | Esophagus | ESCC | 1.56e-17 | 3.75e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:004227422 | Liver | HCC | ribosomal small subunit biogenesis | 65/7958 | 73/18723 | 1.09e-16 | 9.92e-15 | 65 |
| GO:00304901 | Liver | HCC | maturation of SSU-rRNA | 43/7958 | 50/18723 | 2.35e-10 | 8.04e-09 | 43 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:004227420 | Oral cavity | OSCC | ribosomal small subunit biogenesis | 63/7305 | 73/18723 | 7.61e-17 | 6.34e-15 | 63 |
| GO:00304903 | Oral cavity | OSCC | maturation of SSU-rRNA | 41/7305 | 50/18723 | 5.59e-10 | 1.46e-08 | 41 |
| GO:002261328 | Skin | AK | ribonucleoprotein complex biogenesis | 108/1910 | 463/18723 | 8.48e-17 | 6.27e-14 | 108 |
| GO:004225427 | Skin | AK | ribosome biogenesis | 73/1910 | 299/18723 | 8.44e-13 | 2.08e-10 | 73 |
| GO:004227428 | Skin | AK | ribosomal small subunit biogenesis | 29/1910 | 73/18723 | 3.13e-11 | 5.78e-09 | 29 |
| GO:000636420 | Skin | AK | rRNA processing | 53/1910 | 225/18723 | 4.35e-09 | 3.30e-07 | 53 |
| GO:001607220 | Skin | AK | rRNA metabolic process | 54/1910 | 236/18723 | 9.23e-09 | 6.07e-07 | 54 |
| GO:003447016 | Skin | AK | ncRNA processing | 68/1910 | 395/18723 | 1.12e-05 | 2.33e-04 | 68 |
| GO:00304905 | Skin | AK | maturation of SSU-rRNA | 15/1910 | 50/18723 | 9.02e-05 | 1.23e-03 | 15 |
| GO:00346607 | Skin | AK | ncRNA metabolic process | 75/1910 | 485/18723 | 1.64e-04 | 1.93e-03 | 75 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRFBP1 | SNV | Missense_Mutation | c.763N>C | p.Glu255Gln | p.E255Q | Q8NEF9 | protein_coding | tolerated(0.13) | benign(0.123) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SRFBP1 | SNV | Missense_Mutation | c.749N>A | p.Gly250Glu | p.G250E | Q8NEF9 | protein_coding | tolerated(1) | benign(0.001) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SRFBP1 | SNV | Missense_Mutation | c.932N>C | p.Glu311Ala | p.E311A | Q8NEF9 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SRFBP1 | SNV | Missense_Mutation | c.454A>G | p.Asn152Asp | p.N152D | Q8NEF9 | protein_coding | tolerated(0.13) | benign(0.058) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| SRFBP1 | SNV | Missense_Mutation | c.620C>A | p.Pro207His | p.P207H | Q8NEF9 | protein_coding | deleterious(0.01) | benign(0.084) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SRFBP1 | SNV | Missense_Mutation | rs376474484 | c.478C>T | p.Arg160Cys | p.R160C | Q8NEF9 | protein_coding | deleterious(0.04) | benign(0.183) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| SRFBP1 | SNV | Missense_Mutation | novel | c.1274N>A | p.Ile425Asn | p.I425N | Q8NEF9 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| SRFBP1 | SNV | Missense_Mutation | novel | c.943N>A | p.Leu315Ile | p.L315I | Q8NEF9 | protein_coding | tolerated(0.36) | benign(0.069) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SRFBP1 | SNV | Missense_Mutation | c.894N>G | p.Ser298Arg | p.S298R | Q8NEF9 | protein_coding | tolerated(0.07) | benign(0.289) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SRFBP1 | SNV | Missense_Mutation | c.555G>T | p.Lys185Asn | p.K185N | Q8NEF9 | protein_coding | tolerated(0.12) | possibly_damaging(0.541) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |